News 
Market Data 
Discover
Replies to post #231332 on NorthWest Biotherapeutics Inc (NWBO)
06/04/19 7:52 PM
29:20
And as for, I think we’re all aware, neoantigens are really the flavor of the week, or of the month. Everybody is looking, “what is unique about the tumor”, “what is it that we can attack”. We don’t necessarily think that way. We think that sometimes, it makes people pretend that they know more than they do. However, we cannot ignore that part of the field either. And if there are mutations that are unique to the tumor, then those are likely to serve as an antigen for DCVax-Direct to latch onto, present to the immune system, and then target those particular antigens. So while that may not be the be all and end all for immune therapy, it likely is a tool that could come in handy for this particular line of treatment (referring to the DIPG Pediatric trial).
Dr. Bosch was a member of the faculty of the Department of Pathobiology at the University of Washington. He worked at the National Institutes of Health (Bethesda, MD) and the National Institute of Health and Environmental Protection (Bilthoven, the Netherlands) prior to joining the University of Washington. He has authored more than 40 peer-reviewed research publications in immunology and virology and is an inventor on several patent applications on dendritic cell product manufacturing. Dr. Bosch obtained his Ph.D. in Medicine at the University of Leidenthe Netherlands in 1987 and earned an MBA from the University of Washington in 2003. Dr. Bosch worked at the Dutch National Institutes of Health (RIVM) as head of the Department of Molecular Biology, as well as in academia as a professor of Pathobiology.
